Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × idecabtagene vicleucel × 1 year × Clear all

Phase

Phase 2 4 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 218 Cyclophosphamide 121 Nivolumab 116 Carboplatin 94 Gemcitabine 79 Bevacizumab 76 fludarabine 75 Injections 72 venetoclax 71 Specimen Handling 71 Dexamethasone 67 Paclitaxel 64 Magnetic Resonance Spectroscopy 64 Biopsy 57 atezolizumab 56 Cisplatin 51 Ipilimumab 48 Temozolomide 46 Oxaliplatin 44 Azacitidine 44 Rituximab 43 Pemetrexed 43 Docetaxel 42 Lenalidomide 41 Fluorouracil 41 Radiotherapy 40 Cetuximab 40 durvalumab 39 Leucovorin 37 Cytarabine 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04855136 2025-09-11

KarMMa-7

Celgene

Phase 1/2 Terminated

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡